Función cognitiva en pacientes diabetes mellitus tipo 2.

Med Int Mex 09/2011; 27(5):217-223.


Background: Cognitive decline in diabetes mellitus type 2 is well recognized; its etiology is complex due to the diversity of physiopathologic mechanisms potentially involved as well as the high prevalence of comorbility including hypertension, obesity and dyslipidemia. Material and Method: In the review we present recent evidence regarding risk factors related with congnitive decline in diabetic population. Risk factors reviewed included glycemic control, insulin resistance but also obesity, hypertension and metabolic syndrome. Results: Cognitive decline in diabetic patients appear to be mainly related with glycemic control.
Conclusion: Current evidence suggests a multifactorial etiology with uncontrolled chronic glycemia and HbA1c as a marker standing out. Nevertheless, an integral treatment of comorbilities and regular evaluations of cognitive function are required.

Download full-text


Available from: Mayela Rodríguez-Violante, Oct 02, 2015
281 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The search for preventable and remediable risk conditions of cognitive decline is ongoing, but results have thus far been inconsistent. According to the hypothesis of our 10-year prospective study, the predictive values of different risk indicators change over time in a general 75+ population. A population-based sample of 75-, 80-, and 85-year-old individuals (n=650) underwent comprehensive clinical examinations in 1990 in Helsinki, Finland. Cognitive function was assessed by the Mini-Mental State Examination (MMSE) and/or Clinical Dementia Rating (CDR) at baseline and after 1, 5, and 10 years. At baseline, a low MMSE score was associated with age, history of stroke, apolipoprotein E allele epsilon4 (APOE4), and intermittent claudication. After 1 year, cognitive decline was typical of participants suffering from vascular diseases, e.g., heart failure and intermittent claudication. Five-year decline was predicted by the presence of atrial fibrillation (RR [relative risk] 2.8), APOE4 (RR 2.4), elevated C-reactive protein (CRP) (RR 2.3), diabetes mellitus (RR 2.2), and heart failure (RR 1.8). They also tended to increase 5-year all-cause mortality. At 10 years, the decline associated with APOE4 (RR 3.3), slightly elevated serum ionized calcium (RR 3.3), and feelings of loneliness (RR 3.0). Long follow-up of a general aged population explains several inconsistencies of earlier reports. In 75+ individuals, general ill health is a strong associate of cognitive deficits. The strongest predictors of both cognitive decline and mortality are age, APOE4, manifest vascular diseases, and diabetes. The role of new potential predictors, feelings of loneliness and hypercalcemia, needs clinical testing.
    The Journals of Gerontology Series A Biological Sciences and Medical Sciences 04/2004; 59(3):268-74. DOI:10.1093/gerona/59.3.M268 · 5.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is increasingly recognized that diabetes mellitus can lead to long-term complications in the brain. Clinically, these complications are manifested in alterations in cognitive functioning. This paper offers an overview on the impact of diabetes on cognition and provides leads for the evaluation and management of cognitive disturbances in patients with diabetes in a primary care setting. The main message is that while some patient groups appear to be at increased risk of cognitive impairments, in the majority of patients diabetes is not associated with the development cognitive decrements that would be regarded as clinically relevant. Frank impairments of cognition mainly occur in patients above the age of 65, often in association with vascular co-morbidity. Other groups at risk for cognitive decrements are children with an early age at diabetes onset and patients with clinically manifest retinopathy or other microvascular complications. No specific treatment options are available, but for now treatment of vascular risk factors and attention for glycaemic control appears to be a logical approach. Given the recent progress in this field, new treatments to prevent cognitive impairment in patients with diabetes may hopefully become available in the near future.
    Primary Care Diabetes 12/2007; 1(4):187-93. DOI:10.1016/j.pcd.2007.10.002 · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The deleterious effects of diabetes mellitus on the retinal, renal, cardiovascular, and peripheral nervous systems are widely acknowledged. Less attention has been given to the effect of diabetes on cognitive function. Both type 1 and type 2 diabetes mellitus have been associated with reduced performance on numerous domains of cognitive function. The exact pathophysiology of cognitive dysfunction in diabetes is not completely understood, but it is likely that hyperglycemia, vascular disease, hypoglycemia, and insulin resistance play significant roles. Modalities to study the effect of diabetes on the brain have evolved over the years, including neurocognitive testing, evoked response potentials, and magnetic resonance imaging. Although much insightful research has examined cognitive dysfunction in patients with diabetes, more needs to be understood about the mechanisms and natural history of this complication in order to develop strategies for prevention and treatment.
    Endocrine Reviews 07/2008; 29(4):494-511. DOI:10.1210/er.2007-0034 · 21.06 Impact Factor
Show more